Reported occurrence and duration of sick leave among persons with arthritis in paid employment in observational studies
| Mean age (SD) | Sick leave | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Author, year, country | Design | Follow-up | Study population | n (% ♀) | Mean age (SD) | Method | Definition | Proportion | Mean no of days per month (SD) |
| Bjork et al, 2009, SE14 | CC | 3 years after diagnosis | RA, onset of joint swelling≤12 months | 120 (76%) | 47 (12) | R | Any sick leave >14 days in past 3 months at year 1 | 33% | |
| Braakman-Jansen et al, 2012, NL15 | CS | RA ACR '87 <3 months | 62 (55%) | 47 (10) | Q PRODISQ WPAI-GH | Any sick leave in past 3 months Any sick leave in past week | 50% 45% | ||
| Dadodiene et al, 2004, LT16 | CS | RA: ACR ‘87 | 88 (89%) | 49 (–) | Q | At least 1 episode in past year Any sick leave in past year | 50% | 2.7 (2.4) | |
| Doeglas et al, 1995, NL17 | CS | RA: ACR '87 ≤4 years | 69 (52%) | I | Sick leave due to RA at the time of the interview | 22% | |||
| Farahani et al, 2006, CA18 | PC | 12 months | RA with 6 painful or tender joints | 81 etanercept 69 other DMARDs | Q | Any sick leave in past 6 months | 1.0 (2.3) 1.3 (3.0) | ||
| Geuskens et al, 2008, NL19 | CS | RA Non-RA arthritis Inflammatory joint conditions without synovitis | 48 (77%) 74 (58%) 88 (81%) | 46 (11) 44 (10) 44 (10) | Q | Any sick leave in past 6 months 1–7 days 8–14 days >2 weeks | 28% 10% 26% | ||
| Geuskens et al, 2008, NL9 | PC | 1 year | Inflammatory joint conditions <12 months | 210 (72%) | 45 (11) | Q | Any sick leave for >2 weeks in past 6 months | 17% | |
| Gladman et al, 2011, CA20 | PC | 24 months | Active PsA | 40 (–) | Q HLQ | Any sick leave in the past 2 weeks | 0.7 | ||
| Globe et al, 2010, USA21 | RC | RA patients receiving etanercept | 86 (70%) | 50 | I | Sick leave due to RA per month | 12% | 0.1 | |
| Gonzalez-Lopez et al, 2012, MX22 | PC | 48 weeks | RA ACR ‘87 | 123 (73%) | 44 (10) | Q | Sick leave due to RA during 48 weeks follow-up | 24% | 1.5 |
| Hallert et al, 2004, SE23 | PC | 12 months | RA: ACR '87 ≤12 months | 133 | Q | Any sick leave in past 6 months | 62% | 8.7 | |
| Hazes et al, 2010, USA24 | CS | RA—RAPID I RA—RAPID II | 370 245 | Q WPS-RA | Sick leave due to RA in the past month at baseline | 3.9 (8.0) 3.3 (6.8) | |||
| Kristensen et al, 2011, SE28 | RC | 12 months | Active AS at start of treatment | 139 (22%) | 41 (10) | R | Any sick leave ≥15 days in first year | 10% | |
| Krüger et al, 2011, D29 | PC | 12 months | RA patients receiving adalimumab therapy | 1157 (73%) | 46 (9) | Q | Any sick leave in the past 12 months | 1.9 (3.8) | |
| Kvamme et al, 2012, N30 | PC | 2 years | RA PsA AS | 529 235 138 | Q | Any sick leave in past 6 months | 35% 29% 27% | ||
| Mau et al, 1996/1997, D33 34 | CS | RA: ACR ‘87 ≤1 year | 134 (63%) | M: 50 | C | Sick leave due to RA in past 12 months | 55% | 11 in ♂ 8 in ♀ | |
| Merkesdal et al, 2001, D36 | PC | 2 years | RA: ACR '87 ≤1 year | 133 (63%) | 47 (9) | C | Sick leave due to RA in past 12 months | 84% | 7.2 |
| Mittendorf et al, 2008, D37 | PC | 144 weeks | Long-standing RA patients receiving adalimumab | 152 | Q | Sick leave due to RA in past 6 months | 47% | 1.4 (2.8) | |
| Neovius et al, 2011, SE38 | PC | 4 years | RA | 2646 (73%) | 47 (11) | R | Any sick leave for >14 days in past 12 months | 54% | 2.9 |
| Neovius et al, 2011, SE39 | RC | 10 years | RA patients receiving – Mono DMARD therapy – Combination DMARD therapy – Biological therapy | 2796 973 4787 | R | Any sick leave for ≥14 days in past year | 59% 67% 53% | 4.5 8.8 (0.3) 6.6 (0.1) | |
| Ozminkowski et al, 2006, USA40 | CC | 12 months | RA: ICD-9-CM codes | 4490 (41%) | 46 (–) | R HPM | Any sick leave in past year | 69% | 1.1 (1.8) |
| Reisine et al, 2001, USA46 | PC | 10 years | RA: ACR ‘87 part of the National RA Study | 472 (71%) | Q | Sick leave ≥1 day due to RA in past 2 weeks | 13% | ||
| Rohekar and Pope, 2010, CA47 | CS | SpA | 66 | Q | Sick leave due to arthritis in past month | 2.5 (6.2) | |||
| Sany et al, 1998, F48 | CS | RA physician-based, ACR ‘87 | 472 | Q | Any sick leave Sick leave due to RA | 44% 36% | |||
| Silverman et al, 2009, USA49 | RC | 12 months | RA: ICD-9-CM code 714 | 185 | R HPM | Any sick leave in past 12 months | 80% | 1.8 (1.6) | |
| Simons et al, 2012, USA50 | CS | RA ICD-9 code 714 | 37 45 42 | Q | Any sick leave in past year 2004 2005 2006 | 1 (2.6) 0.9 (2.0) 0.8 (1.6) | |||
| Søgaard et al, 2010, DK52 | CS | RA: ACR ‘87 | 1049 | Q HLQ | Sick leave due to RA in past 2 weeks | 7% | 1.1 | ||
| Stockl et al, 2010, USA53 | PC | 6 months | RA physician-based | 48 | Q WPAI | Any sick leave in past 7 days at month 6 | 7% | ||
| Sullivan et al, 2010, USA55 | CS | RA: ICD-9-CM code 714 | 125 | Q | Any sick leave in past year | 0.7 | |||
| Verstappen et al, 2005, NL3 | CS | RA: ACR ‘87 | 142 (65%) | 46 (10) | Q HLQ | Sick leave due to RA in past 2 weeks | 16% | 1.8 (5.2) | |
| Zhang et al, 2010, UK12 59 | CS | RA physician-based<3 years complaints | 136 | 48 (10) | Q WPAI-GH | Any sick leave in the past 7 days | 19% | ||
| Zhang et al, 2011, UK61 | PC | 2 weeks | RA physician-based <3 years complaints | 110 | Q VOLP | Any sick leave in the past 3 months at week 2 | 40% | 1.2 (2.8) | |
| Zhang et al, 2011, CA62 | PC | 52 weeks | RA: ACR '87 >3 months, <2 years | 205 (69%) | 45 | Q | Any sick leave in the past 8 weeks at week 52 | 15% | 0.9 (3.1) |
| Ziegler et al, 2010, D63 | CS | RA | 1617 (72%) | Q | Sick leave due to RA in past 12 months | 27% | 0.7 | ||
| Zirkzee et al, 2008, NL64 | PC | 12 months | Early arthritis <2 years | 69 (55%) | M: 42 | Q | Sick leave ≥2 weeks due to arthritis in past 12 months 2–4 weeks 1–3 months 3–12 months | 10% 3% 12% | |
Author, year, country: CA=Canada, D=Germany, DK=Denmark, F=France, FI=Finland, LT=Lithuania, MX=Mexico, N=Norway, NL=the Netherlands, SE=Sweden, UK=United Kingdom, USA=United States of America, Design: CC=case-control, CS=cross-sectional, PC=prospective cohort, RC=retrospective cohort.
Study population: RA=rheumatoid arthritis, ACR ‘87=satisfied the 1987 American College of Rheumatology criteria, PsA=psoriatic arthritis, AS=ankylosing spondylitis, SpA=spondyloarthropathy, ICD-9-CM=International Classification of Diseases-9-Clinical Modification.
n (%): DMARDs=Disease Modifying Anti Rheumatic Drugs; Age: M=median value reported.
Method: R=registry, Q=questionnaire, I=interview, C=certified by physician, HPM=Health and Productivity Management, HLQ=Health and Labour Questionnaire, WPS-RA=RA-specific Work Productivity Survey, WPAI-GH=Work Productivity and Activity Impairment -general health, PRODISQ=PROductivity and DISease Questionnaire, VOLP=Valuation of Lost Productivity questionnaire.